Clinical Trial Update: Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study evaluating the combination of venetoclax and azacitidine for relapsed or refractory high-risk myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Therapy-related Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING